BioCryst Pharmaceuticals Reports Reduced Loss, Revenue Growth

BioCryst Pharmaceuticals sees improvement with a reduced net loss of $26.8 million in Q4. A rebound in revenues highlights the company's potential. Investors should note this upward trend and the revised revenue outlook for 2025.

Date: 24-02-2025

AI Rating: 5

**Earnings Per Share (EPS)**: BioCryst reported a net loss of $0.13 per share for the fourth quarter, which, although negative, indicates an improvement from the previous year's loss of $0.31 per share. However, this was worse than analysts' expectations of a loss of $0.06, suggesting a fairly disappointing performance relative to market expectations. **Net Income**: The net loss reported was $26.8 million, down from a larger loss of $61.7 million in the same quarter of the previous year, which indicates that the company's financial situation is improving. This reduction in losses could positively influence investor sentiment. **Revenue Growth**: Total revenues substantially increased to $131.5 million, up from $93.4 million a year prior, demonstrating significant growth. The revenue growth prompted by ORLADEYO net revenue, which surged to $124.2 million from $90.9 million, is a crucial factor for the company's sustained health. **Outlook**: The revised full-year 2025 outlook indicates a projected total revenue of between $560 million and $575 million, up from prior guidance of $540 million to $560 million. This upward revision suggests that the company is anticipating better performance in the near future. **Future Prospects**: BioCryst's expectation of approaching positive EPS and cash flow in the latter half of 2025, with profitability anticipated for the full year 2026, adds a layer of positive sentiment for investors looking at long-term growth. Moreover, an estimated 20 percent annual CAGR for revenue over the next three years adds to the bullish outlook for the company.

Stocks: BCRX